HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases

Abstract

Complement cascade is a defence mechanism useful for eliminating pathogenic microorganisms and damaged cells. However, activation of alternative complement system can also cause inflammation and promote kidney and retinal disease progression. Inflammation causes tissue hypoxia, which induces hypoxia-inducible factor (HIF) and HIF helps the body to adapt to inflammation. In this study, we investigated the effect of HIF stabilizer desidustat in complement-mediated diseases. Oral administration of desidustat (15 mg/kg) was effective to reduce the kidney injury in mice that was induced by either lipopolysaccharide (LPS), doxorubicin or bovine serum albumin (BSA)-overload. Complement activation-induced membrane attack complex (MAC) formation and factor B activity were also reduced by desidustat treatment. In addition, desidustat was effective against membranous nephropathy caused by cationic BSA and retinal degeneration induced by sodium iodate in mice. C3-deposition, proteinuria, malondialdehyde, and interleukin-1ß were decreased and superoxide dismutase was increased by desidustat treatment in cBSA-induced membranous nephropathy. Desidustat specifically inhibited alternative complement system, without affecting the lectin-, or classical complement pathway. This effect appears to be mediated by inhibition of factor B. These data demonstrate the potential therapeutic value of HIF stabilization by desidustat in treatment of complement-mediated diseases.

Keywords

complement system - prolyl hydroxylase inhibitor - glomerulonephritis

Publication History

Received: 26 March 2024

Accepted: 17 June 2024

Article published online:
11 July 2024

• References

• 1 Sjöberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol 2009; 30: 83-90
• 2 Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Mol Immunol 2020; 128: 175-187
• 3 Colgan SP, Furuta GT, Taylor CT. Hypoxia and Innate Immunity: Keeping Up with the HIFsters. Annu Rev Immunol 2020; 38: 341-363
• 4 Joharapurkar AA, Pandya VB, Patel VJ. et al. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. J Med Chem 2018; 61: 6964-6982
• 5 Patel V, Joharapurkar A, Kshirsagar S. et al. Hepcidin inhibition improves iron homeostasis in ferrous sulfate and LPS treatment model in mice. Drug Res 2021; 71: 528-534
• 6 Jain M, Joharapurkar A, Patel V. et al. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation. Eur J Pharmacol 2019; 843: 113-120
• 7 Parmar DV, Kansagra KA, Patel JC. et al. on behalf of the ZYAN1 Trial Investigators. Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study. Am J Nephrol 2019; 49: 470-478
• 8 Joharapurkar AA, Patel VJ, Kshirsagar SG. et al. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress. Drug Dev Res 2021; 82: 852-860
• 9 Animals NRC (US) C for the U of the G for the, Laboratory C and U of. Guide for the Care and Use of Laboratory Animals. Washington, D.C.: National Academies Press; 2011
• 10 Harboe M, Garred P, Lindstad JK. et al. The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation. The Journal of Immunology 2012; 189: 2606-2613
• 11 Le GT, Abbenante G, Fairlie DP. Profiling the enzymatic properties and inhibition of human complement factor B. J Biol Chem 2007; 282: 34809-34816
• 12 Wang W, Sheng L, Chen Y. et al. Total coumarin derivates from Hydrangea paniculata attenuate renal injuries in cationized-BSA induced membranous nephropathy by inhibiting complement activation and interleukin 10-mediated interstitial fibrosis. Phytomedicine 2022; 96: 153886
• 13 Patel VJ, Joharapurkar A, Jain MR. The Perspective of Using Flow Cytometry for Unpuzzling Hypoxia-Inducible Factors Signalling. Drug Res 2023; 74: 113-122
• 14 Pandya PH, Fisher AJ, Mickler EA. et al. Hypoxia-Inducible Factor-1α Regulates CD55 in Airway Epithelium. Am J Respir Cell Mol Biol 2016; 55: 889-898
• 15 Khan MA, Shamma T, Kazmi S. et al. Hypoxia-induced complement dysregulation is associated with microvascular impairments in mouse tracheal transplants. J Transl Med 2020; 18: 147
• 16 Fu X, Ju J, Lin Z. et al. Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice. Sci Rep 2016; 6: 30239
• 17 Ikeda Y, Horinouchi Y, Hamano H. et al. Dietary iron restriction alleviates renal tubulointerstitial injury induced by protein overload in mice. Sci Rep 2017; 7: 10621
• 18 Tang Z, Lu B, Hatch E. et al. C3a Mediates Epithelial-to-Mesenchymal Transition in Proteinuric Nephropathy. Journal of the American Society of Nephrology 2009; 20: 593-603
• 19 Jain MR, Joharapurkar AA, Pandya V. et al. Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res 2016; 66: 107-112
• 20 Madaio MP, Harrington JT. The Diagnosis of Glomerular Diseases: acute glomerulonephritis and the nephrotic syndrome. Arch Intern Med 2001; 161: 25-34
• 21 Janeway C, Travers P, Walport M. et al. Immunobiology: The Immune System in Health and Disease. 5. Aufl. New York: Garland Science; 2001
• 22 Schubart A, Anderson K, Mainolfi N. et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proceedings of the National Academy of Sciences 2019; 116: 7926-7931
• 23 Kiriakidis S, Hoer SS, Burrows N. et al. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor. Kidney Int 2017; 92: 900-908
• 24 Borza DB, Zhang JJ, Beck LH. et al. Mouse models of membranous nephropathy: the road less travelled by. Am J Clin Exp Immunol 2013; 2: 135-145
• 25 Motiram Kakalij R, Tejaswini G, Patil MA. et al. Vanillic Acid Ameliorates Cationic Bovine Serum Albumin Induced Immune Complex Glomerulonephritis in BALB/c Mice. Drug Dev Res 2016; 77: 171-179
• 26 Ostrycharz E, Hukowska-Szematowicz B. New Insights into the Role of the Complement System in Human Viral Diseases. Biomolecules 2022; 12: 226
• 27 Dinarello C. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652
• 28 Armento A, Ueffing M, Clark SJ. The complement system in age-related macular degeneration. Cellular and Molecular Life Sciences 2021; 78: 4487-4505
• 29 Chowers G, Cohen M, Marks-Ohana D. et al. Course of sodium iodate–induced retinal degeneration in albino and pigmented mice. Invest Ophthalmol Vis Sci 2017; 58: 2239-2249
• 30 Wang S, Du L, Yuan S. et al. Complement C3a receptor inactivation attenuates retinal degeneration induced by oxidative damage. Front Neurosci 2022; 16: 951491
• 31 Janssens LK, Stove CP. Sensing an Oxygen Sensor: Development and Application of Activity-Based Assays Directly Monitoring HIF Heterodimerization. Anal Chem 2021; 93: 14462-14470
• 32 Gang S, Khetan P, Varade D. et al. Study Investigator Group. Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D). Am J Nephrol 2022; 53: 343-351
• 33 Johnson HN, Prasad-Reddy L. Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease. Ann Pharmacother 2024; 14 10600280241241563 DOI: 10.1177/10600280241241563. Online ahead of print
• 34 McCallum W, Weiner DE. HIF-PHIs for Anemia Management in CKD: Potential and Uncertainty ASCEND. Clin J Am Soc Nephrol 2022; 17: 1255-1258
• 35 Kansagra KA, Parmar D, Jani RH. et al. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers. Clin Pharmacokinet 2018; 57: 87-102